Natixis Advisors LLC Boosts Stock Position in Bruker Corporation $BRKR

Natixis Advisors LLC lifted its position in shares of Bruker Corporation (NASDAQ:BRKR) by 31.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 627,672 shares of the medical research company’s stock after buying an additional 148,915 shares during the period. Natixis Advisors LLC owned about 0.41% of Bruker worth $20,394,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Spire Wealth Management raised its position in Bruker by 85.3% in the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after purchasing an additional 665 shares during the period. Jones Financial Companies Lllp increased its holdings in shares of Bruker by 79.7% in the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock worth $86,000 after buying an additional 1,230 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Bruker in the 2nd quarter valued at about $87,000. EverSource Wealth Advisors LLC boosted its holdings in Bruker by 51.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 942 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in Bruker by 727.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,100 shares of the medical research company’s stock worth $166,000 after acquiring an additional 4,484 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

BRKR has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. The Goldman Sachs Group lowered their price target on shares of Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. UBS Group reissued a “neutral” rating and set a $49.00 price target on shares of Bruker in a research report on Friday, February 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. Finally, Barclays lowered their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $50.38.

Bruker Trading Up 0.6%

Shares of BRKR opened at $36.81 on Thursday. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The stock has a market cap of $5.60 billion, a PE ratio of -245.40, a PEG ratio of 2.19 and a beta of 1.19. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22. The stock has a 50 day simple moving average of $44.03 and a 200-day simple moving average of $41.06.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same period in the prior year, the firm earned $0.76 EPS. Bruker’s quarterly revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s dividend payout ratio is presently -133.33%.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at $6,319,395.60. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 27.30% of the stock is owned by company insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.